{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Grade 3+ Adverse Events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Grade 4+ Adverse Events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 5 Adverse Events"}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"Assessed per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. Included are the toxicities at least possibly related to the study drug.","groups":[{"description":"Patients receive oral sunitinib malate once daily on days 1-42. Treatment repeats every 42 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Kinase Inhibitor Therapy)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From the time of first treatment to up to 30 days after the last day of study drug treatment","title":"Toxicity","type":"SECONDARY","unitOfMeasure":"participants"}